Macro and Strategy Research - The US non-farm employment data for February was significantly below market expectations, continuing the slowdown trend since the end of 2025. The labor participation rate has slightly decreased after adjustments, and while the unemployment rate has increased, it remains within a controllable range. Inflation data appears stable, aligning with market expectations, but core goods are outperforming core services, indicating tariff transmission effects in sectors like apparel [2][3] - In Europe, the reliance on oil imports is higher, making the situation more challenging, with markets pricing in a potential interest rate hike by the European Central Bank this year [3] Fixed Income Research - February CPI showed an increase in both year-on-year and month-on-month growth, driven by seasonal factors and rising international oil prices, which also impacted PPI. The core inflation is expected to seasonally decline in March, with input factors remaining significant [6] - The central bank net injected 500 billion yuan into the market, with funding prices slightly rising. The issuance of bonds in the primary market decreased, with a total of 63 bonds issued, amounting to 414.2 billion yuan [6][8] - The long-term interest rates are under pressure due to rising inflation expectations, particularly from the increase in international oil prices. The market is advised to cautiously observe inflation changes in the short term [7][8] Industry Research - Eli Lilly has invested $3 billion to enhance its supply chain in China, indicating strong interest in the Chinese pharmaceutical market [9] - Several pharmaceutical companies have been added to the Hong Kong Stock Connect list, reflecting growing investor interest [10] - The SW pharmaceutical sector index rose by 2.49% during the week, with all sub-sectors showing gains. The overall industry P/E ratio is 49.25 times, with a valuation premium of 245% compared to the CSI 300 [10] - The report maintains a "neutral" rating for the industry, with specific buy and hold recommendations for companies like Heng Rui Medicine and WuXi AppTec, while also highlighting the potential impact of rising raw material prices on pharmaceutical companies [11]

Core Viewpoint - The article discusses the growth of the intravascular ultrasound (IVUS) industry, driven by three main factors: the increasing volume of PCI surgeries, the rising penetration rate of IVUS in PCI procedures, and the significant potential for domestic replacement of imported IVUS products [9][24][26]. Group 1: PCI Surgery Volume Growth - The mortality rate from coronary artery disease (CAD) remains high, with a significant number of patients. In China, the death rates for rural and urban residents due to coronary heart disease were 14.82 and 13.51 per 10,000 respectively in 2021 [14]. - The number of CAD patients in China is projected to grow from 27 million in 2022 to 32 million by 2030, with a CAGR of approximately 2.2%. Globally, the number of CAD patients is expected to increase from 213 million to 250 million during the same period, with a CAGR of about 2.0% [14][19]. - PCI has become the mainstream treatment for CAD, with advantages such as minimal invasiveness, effective results, and quick recovery times [14]. Group 2: Increasing IVUS Penetration in PCI - The penetration rate of IVUS in PCI procedures in China was only 15.4% in 2021, significantly lower than developed countries. The U.S. and Japan have penetration rates exceeding 23% [22][26]. - The domestic IVUS penetration rate has rapidly increased from 8.5% in 2020 to 15.4% in 2021, indicating a near doubling within a year. The usage of IVUS consumables in China is projected to rise from approximately 322,800 units in 2022 to 553,700 units in 2024 [26]. - The overall market size for IVUS in China is expected to grow from about 1.76 billion RMB in 2024 to 5.11 billion RMB by 2030, with a CAGR of 19.4% [26]. Group 3: Domestic Replacement Potential - The IVUS market in China is currently dominated by imported brands, with Boston Scientific and Philips holding 81.4% of the market share in 2024. Domestic brands like Beixin Life and Kaili Medical are gradually entering the market [24]. - As domestic supply increases and product quality improves, the trend towards domestic replacement is expected to accelerate, supported by favorable policies and market conditions [24][26]. - The domestic IVUS market is characterized by a growing number of approved products, with 10 products already on the market and one in clinical research [24].

Investment Rating - The report does not explicitly state an investment rating for the IVUS industry but highlights significant growth potential driven by multiple factors. Core Insights - The IVUS industry is experiencing growth due to three main factors: increasing PCI surgery volumes, rising IVUS penetration in PCI procedures, and substantial domestic replacement opportunities for imported products. Summary by Sections Market Overview - The IVUS technology is essential for guiding PCI (Percutaneous Coronary Intervention) procedures, providing real-time imaging of vascular structures and improving diagnostic accuracy [14][21]. Growth Drivers - **Increasing PCI Surgery Volumes**: The number of PCI procedures is expected to grow significantly, with China's PCI surgeries projected to increase from 1.906 million in 2024 to 4.298 million by 2030, reflecting a CAGR of 14.5% [27][28]. - **Rising IVUS Penetration**: The penetration rate of IVUS in PCI procedures in China is expected to rise from 15.4% in 2021, with projections indicating a market size growth from 1.76 billion RMB in 2024 to 5.11 billion RMB by 2030, achieving a CAGR of 19.4% [38][39]. - **Domestic Replacement Opportunities**: The IVUS market in China is currently dominated by imported brands, with local manufacturers like Beixin Life and Kaili Medical beginning to capture market share. The domestic market share for Beixin Life is projected to reach 10.6% by 2024 [39][40]. Competitive Landscape - The IVUS market is characterized by a mix of domestic and international players, with significant room for growth in domestic production and innovation. The report identifies key players such as Beixin Life and Kaili Medical as emerging competitors in the IVUS space [44][47].

Group 1 - Vitasoy International (00345) reported a 6% year-on-year decrease in revenue and a 7% decrease in gross profit for the six months ending September 30, 2025, primarily due to weak market conditions in mainland China [1] - Shandong Xinhua Pharmaceutical (00719) saw a rise of over 2% after receiving approval from the National Medical Products Administration for the registration of a drug [1] - China Biologic Products (01177) increased by over 2% following the publication of positive Phase II clinical trial results for TQB2102 in HER2-positive breast cancer in a prestigious journal [1] - GDS Holdings (09698) rose over 4% after reporting a net income of 2.887 billion RMB for Q3, a 10.2% year-on-year increase, and a net profit margin of 25.2% [1] Group 2 - GaYa Optical (00907) surged by 49.12% after announcing a profit forecast of 8.8 million to 9.6 million HKD for the six months ending September 30, 2025, a significant turnaround from a loss of 13.8 million HKD in the same period last year [2] - Green Leaf Pharmaceutical (02186) rose nearly 2% after announcing FDA approval for clinical trials of a new drug [2] - Hengrui Medicine (01276) increased by over 5% after receiving approval for clinical trials of two drugs [2] - Meituan-W (03690) saw a 6% rise as Alibaba's CFO announced increased investment in Taobao Flash Purchase [2] Group 3 - Alibaba Group (09988) experienced a nearly 2% drop after reporting a 5% year-on-year revenue increase for Q2, but a significant 78% decline in adjusted EBITA [3] - Junshi Biosciences (01877) rose nearly 4% after announcing successful Phase III trial results for a drug in treating non-small cell lung cancer [4] Group 4 - Abercrombie & Fitch (ANF.US) surged by 37.54% after reporting Q3 earnings that exceeded expectations with an adjusted EPS of $2.36 and a 7% year-on-year sales increase [5] - Symbotic (SYM.US) rose by 39.36% after reporting Q4 revenue of $618 million despite a net loss [5] - Novo Nordisk (NVO.US) increased by 4.65% following positive results for a new weight loss and diabetes drug [5] - Kohl's (KSS.US) saw a 42.53% increase after exceeding Q3 earnings expectations and raising full-year guidance [6] - Alibaba (BABA.US) rose by 2.31% after reporting a 5% year-on-year revenue increase, although adjusted net profit fell by 72% [6] - Pony.ai (PONY.US) increased by 5.88% after announcing profitability for its seventh-generation Robotaxi [6]

分组1 - Weili Medical plans to distribute a cash dividend of 2 yuan per 10 shares to all shareholders, based on an undistributed profit of 704 million yuan as of September 30, 2025 [1] - Tongding Interconnect's shareholder plans to reduce their stake by up to 0.49%, equating to a maximum of 605,800 shares [1] - Caitong Securities has received approval from the China Securities Regulatory Commission to issue short-term corporate bonds with a total face value of up to 5 billion yuan [1] 分组2 - Youfu Food intends to use 70 million yuan of its own funds to invest in wealth management products with expected annual returns of up to 4.2% [3] - Keres received an administrative regulatory decision from the Guangdong Securities Regulatory Bureau for violations related to accounts receivable aging calculations and related party transactions [5] - Ouma Software's controlling shareholder has completed the transfer of state-owned equity, changing the controlling shareholder to Shandong Guotou [7] 分组3 - ST Huapeng's wholly-owned subsidiary has completed a major overhaul project and is now in production [8] - Beiqi Blue Valley has received approval from the China Securities Regulatory Commission for a stock issuance to specific investors [8] - Weijie Chuangxin received a government subsidy of 5 million yuan, accounting for 21.07% of its projected net profit for 2024 [9] 分组4 - China Resources Double Crane's subsidiary has received a drug registration certificate for a hypertension treatment drug [11] - Huafeng shares are continuing to suspend trading due to a planned change in control [13] - Kaifa Electric's shareholder plans to transfer 36.6869 million shares, representing 11.63% of the total share capital [14] 分组5 - Heng Rui Medicine has received approval for two clinical trials for innovative anti-tumor drugs [15] - Kosen Technology plans to invest 30 million USD to establish a new production base in Malaysia [17] - Sanxing Medical's subsidiary is expected to win a procurement project from the State Grid worth approximately 107 million yuan [18] 分组6 - Sitai Li's subsidiary has received a drug registration certificate for a contrast agent used in MRI [21] - Daren Tang's subsidiary has received a drug registration certificate for a pain relief gel [22] - Saike Xide has received approval for three medical device products, expanding its product range in the in vitro diagnostic field [23] 分组7 - Hasa Lian has elected a new chairman and vice chairman for its board of directors [24] - Two-sided Needle's subsidiary plans to invest 68.8522 million yuan in a production base expansion project [25] - Sunshine Nuohe plans to transfer 70% of its controlling subsidiary's equity for 2 million yuan [26] 分组8 - Hengbang shares received an administrative regulatory decision from the Shandong Securities Regulatory Bureau for failing to complete the election of independent directors [27] - Huali shares plan to sign a related transaction contract worth approximately 59.2847 million yuan [28] - Shangwei shares plan to invest 520.4 million yuan to gain a controlling stake in Sichuan Zhongfu Taihua [30] 分组9 - Zejing Pharmaceutical's ZG006 has been included in the list of breakthrough therapeutic varieties for treating advanced neuroendocrine cancer [32] - Yaopi Glass's shareholder plans to reduce their stake by up to 2.26%, equating to a maximum of 21.1469 million shares [34] - Huate Gas has initiated a major lawsuit involving a claim of 180 million yuan [36] 分组10 - Zhongchumei's controlling shareholder plans to increase their stake by between 42 million and 80 million yuan [37] - Huitong shares' shareholder plans to reduce their stake by up to 1% [38] - Miaowei Exhibition plans to apply for an initial public offering of H shares on the Hong Kong Stock Exchange [40] 分组11 - Tianqi Lithium's subsidiary has appealed to the Chilean Supreme Court regarding a partnership agreement with SQM and Codelco [42] - Naxin Micro plans to repurchase shares worth between 200 million and 400 million yuan [44] - Pingao shares have reported significant uncertainty regarding future business development and profitability [46] 分组12 - Shunyu shares have been pre-selected for a project worth 1.023 billion yuan [48] - Zhongyuan Neipei plans to acquire a 2.5% share in an aerospace industry fund for 50 million yuan [50] - Huifa Food's shareholder plans to reduce their stake by up to 3%, equating to a maximum of 727.14 million shares [53] 分组13 - Junshi Biosciences' subcutaneous PD-1 new formulation has reached its primary endpoint in a Phase III clinical trial [54] - Industrial Fulian clarified that it has not lowered its fourth-quarter profit target amid market rumors [55] - Longpan Technology's subsidiary has signed a major supply agreement for lithium iron phosphate materials, significantly increasing the supply volume [56]

Core Viewpoint - Junshi Biosciences (688180.SH) announced that its product Toripalimab injection (subcutaneous) has achieved the primary endpoint in a Phase III clinical study for the treatment of recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC) in combination with chemotherapy [1][2] Group 1: Clinical Research - The JS001sc-002-III-NSCLC study is a multicenter, open-label, randomized controlled Phase III clinical trial, marking the first Phase III clinical study for a domestic PD-1 subcutaneous formulation [2] - The study aims to compare the drug exposure, efficacy, and safety of JS001sc and Toripalimab injection in patients with recurrent or metastatic non-squamous NSCLC [2] - Results indicate that the drug exposure of JS001sc is non-inferior to that of Toripalimab injection, with similar efficacy and safety profiles for both treatments [2] Group 2: Market Context - According to GLOBOCAN 2022, there were 1.06 million new lung cancer cases in China in 2022, accounting for 22.0% of all new cancer cases, with lung cancer deaths reaching 730,000, representing 28.5% of cancer deaths [1] - Non-small cell lung cancer (NSCLC) constitutes approximately 85% of all lung cancer cases, with non-squamous NSCLC patients making up about 65% of NSCLC cases [1] - There is a pressing clinical need to enhance the convenience of immunotherapy, as current domestic immunotherapy drugs are primarily intravenous formulations, which are time-consuming and inconvenient for patients [2]